Michael Dickinson: In our article, we report on the development of rapid CART – YTB323, also known as rapcabtagene autoleucel.
Michael Dickinson, , recently shared on LinkedIn:
“RAPID CAR-T!
Autologous CAR-T cells have transformed the treatment of B-cell lymphoma. They usually take a few weeks to manufacture, and T-cell fitness is very important for their effectiveness.
In our article highlighted on the cover of CANCER DISCOVERY and in an accompanying editorial, we report on the development of rapid CART – YTB323 (Young T Bombers!) also known as rapcabtagene autoleucel.
This is a new CAR-T product that can be manufactured in just a few days, which has all the good stuff of auto-CAR-T cells and SPEED which is important in the clinic. The T-cells have a stem-like phenotype which we know corresponds to clinical potency.
This article presents both the translational work of the team at Novartis and the phase 1 data in DLBCL which are very promising, with a high CR rate and excellent toxicity.
Congratulations to my co-investigators around the world and the discovery team.
And as always: A big thanks to my team at Peter MacCallum Cancer Centre where we achieved extremely rapid trial activation, treated the first patients in the world, and helped develop an understanding of this new CAR-T cell product. So excited to be a part of this.”
Photo taken from Michael Dickinson
For the article click here.
Source: Michael Dickinson/LinkedIn